Down Syndrome, caused by an extra copy of chromosome 21, is one of the most common chromosomal disorders, marked by ...

The Food and Drug Administration’s (FDA) approval of the first blood test to aid in the diagnosis of Alzheimer’s disease ...

The agency granted clearances for tests for cancer and precancer disorders, infectious respiratory diseases, and risk of sepsis and septic shock, among others.

A new Fujirebio Diagnostics blood test identifies beta-amyloid, a brain plaque that is a key marker for Alzheimer’s disease.

Ixico said it was contracted by Fujirebio Diagnostics Inc, a Tokyo-based biomarker research company, to assist with the development of a new blood-based test for Alzheimer's disease called Lumipulse.

Although facing a potential Alzheimer’s diagnosis is daunting, waiting only limits a person’s options. If you’re concerned ...

The U.S. Food and Drug Administration has approved the marketing of a new tool to that can test a person’s blood to diagnose ...

The Food and Drug Administration (FDA) cleared the first blood test recently to help diagnose Alzheimer's disease.

Malvern biotechnology company Fujirebio Diagnostics has developed a revolutionary new test to diagnose Alzheimer’s disease, ...

As an Alzheimer’s caregiver writes, a biomarker test was recently approved by the FDA and can lead to earlier treatment.

H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G sTREM2 assay for the fully automated LUMIPULSE® G immunoassay analyzers. This CLE ...

Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality RUO and in vitro diagnostics (IVD) testing. It has more than 50 years' accumulated experience in the ...